Provided by Tiger Trade Technology Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.03
-0.0300-2.84%
Volume:276.32K
Turnover:285.72K
Market Cap:127.10M
PE:-1.52
High:1.06
Open:1.06
Low:1.02
Close:1.06
52wk High:3.06
52wk Low:1.00
Shares:124.00M
Float Shares:106.47M
Volume Ratio:1.26
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6748
EPS(LYR):-0.7517
ROE:-35522.62%
ROA:-42.78%
PB:6.98
PE(LYR):-1.36

Loading ...

Milestone Pharma CEO Joseph Oliveto disposes of 36,500 shares for $82,490

Reuters
·
Apr 21

Milestone launches Phase 4 RESET-PSVT registry for CARDAMYST nasal spray in adults

Reuters
·
Apr 10

Milestone Pharmaceuticals Announces Reset-Psvt Registry to Generate Real-World Evidence on Cardamyst™ (Etripamil) Nasal Spray in Patients With Psvt

THOMSON REUTERS
·
Apr 10

Milestone Pharma to Present at Needham Virtual Healthcare Conference

Reuters
·
Apr 07

Milestone Pharmaceuticals grants 123,000 inducement stock options to new hires

Reuters
·
Apr 02

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 02

Milestone says Express Scripts adds CARDAMYST to commercial national formularies

Reuters
·
Apr 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Mar 31

Milestone Pharmaceuticals files Form 3 for GC and Chief Compliance Officer David I. Sandoval

Reuters
·
Mar 24

Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals

TIPRANKS
·
Mar 21

Why Milestone Pharma Stock Is Taking A Dive Today

Benzinga Earnings
·
Mar 20

Milestone Pharmaceuticals Q4 EPS $(0.16), Inline, Sales $1.546M Beat $1.200M Estimate

Benzinga Earnings
·
Mar 20

Milestone Pharmaceuticals Inc - Q4 2025 Net Loss Was $17.4 Mln or $0.16 per Share

THOMSON REUTERS
·
Mar 20

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of Cardamyst™ (Etripamil) Nasal Spray for the Treatment of Psvt

THOMSON REUTERS
·
Mar 20

Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST(TM) (etripamil) Nasal Spray for the Treatment of PSVT

Dow Jones
·
Mar 20

Milestone Pharmaceuticals FY2025 net loss widens 51.9% to USD 63.06 million, commercial expenses more than doubled to USD 28.3 million

Reuters
·
Mar 20

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Mar 20

Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
Mar 18

Milestone Pharmaceuticals to present CARDAMYST nasal spray data and host an expert theater at ACC.26

Reuters
·
Mar 16

Milestone Pharmaceuticals to Report Q4 and Full-Year 2025 Financial Results and Host Investor Call

Reuters
·
Mar 12